Table 1.
Baseline characteristics of the advanced hepatocellular carcinoma patients who received immune checkpoint inhibitor plus proton beam radiotherapy
| Patient characteristics | Overall N = 29 | PBT curative purpose N = 13 | PBT palliative control N = 16 |
|---|---|---|---|
| Age (years) | 61.0 ± 10.0 | 60.0 ± 10.3 | 61.5 ± 9.9 |
| > 60 y/o, n (%) | 18 (62.1) | 7 (53.8) | 11 (68.8) |
| Male, n (%) | 20 (69.0) | 9 (69.2) | 11 (68.8) |
| ECOG PS, n (%) | |||
| 0 | 16 (55.2) | 8 (61.5) | 8 (50.0) |
| 1 | 13 (44.8) | 5 (38.5) | 8 (50.0) |
| Child-Pugh score, n (%) | |||
| A5 | 23 (79.3) | 11 (84.6) | 12 (75.0) |
| A6 | 6 (20.7) | 2 (15.4) | 4 (25.0) |
| ALBI, n (%) | |||
| Grade 1 | 17 (58.6) | 9 (69.2) | 8 (50.0) |
| Grade 2 | 12 (41.4) | 4 (30.8) | 8 (50.0) |
| BCLC, n (%) | |||
| B | 3 (10.3) | 2 (15.4) | 1 (6.3) |
| C | 26 (89.7) | 11 (84.6) | 15 (93.8) |
| BMI ≥ 25 kg/m2, n (%) | 9 (31.0) | 6 (46.2) | 3 (18.8) |
| AFP ≥ 400 ng/mL, n (%) | 11 (37.9)* | 3 (23.1)* | 8 (50.0) |
| Hepatitis virus, n (%) | |||
| HBsAg positive | 15 (51.7) | 4 (30.8) | 11 (68.8) |
| Anti-HCV positive | 6 (20.7) | 3 (23.1) | 3 (18.8) |
| Alcohol, n (%) | 9 (31.0) | 3 (23.1) | 6 (37.5) |
| Macrovascular invasion, n (%) | 17 (58.6) | 8 (61.5) | 9 (56.3) |
| Extrahepatic metastasis, n (%) | 17 (58.6) | 6 (46.2) | 11 (68.8) |
| Tumor diameter ≥ 5 cm | 19 (65.5) | 7 (53.8) | 12 (75.0) |
| Previous locoregional treatment, n (%) | 15 (51.7) | 9 (69.2) | 6 (37.5) |
| Systemic treatment, n (%) | |||
| First-line | 21 (72.4) | 11 (84.6) | 9 (56.3) |
| ≥ second-line | 8 (38.1) | 2 (15.4) | 7 (43.8) |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status; ALBI, Albumin-Bilirubin Index; BCLC, Barcelona Clinic Liver Cancer; BMI, Body Mass Index; AFP, Alpha-Fetoprotein; HBsAg, Hepatitis B Surface Antigen; HCV, Hepatitis C Virus; PBT, Proton Beam Radiotherapy.
*
One patient missing baseline AFP data.